OPEN LETTER – We stay open for you and your patients – Please read

  • OPEN LETTER – We stay open for you and your patients – Please read

    ARCHIMEDlife News , Publications March 15, 2020

    We stay open for you and your patients! We used the last days to prepare us to continue our work and services on the highest… Read more

  • New cut-offs for lysosomal enzyme activities.

    ARCHIMEDlife News June 6, 2019
    We are happy to inform you that we have introduced a new diagnostic assay for the analysis of lysosomal enzyme activities from Dried Blood Spots… Read more
  • Improving our ability to diagnose Hemoglobinopathies.

    ARCHIMEDlife News October 1, 2018

    Results of a prospective study using High-Resolution Mass Spectrometry. The goal of our study, in cooperation with the University Medical Center Hamburg in Eppendorf Germany,… Read more

  • First LEA assay launched

    ARCHIMEDlife News March 14, 2018
    LEA2 MPS Panel Our first LEA2 (Lysosomal Enzyme Activity) assay has now been started and with it several mucopolysaccharidoses (MPS) can be diagnosed from one… Read more
  • Awarded work: Hemoglobinopathies and Thalassemias

    Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now starting into a prospective study in… Read more
  • Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine (Lyso-Gb3) and time to initiation of enzyme replacement therapy, an observational study

    Publications March 7, 2018
    Introduction: Methods: Results:  Conclusion: Authors / corresponding author*  JAlbinaNowakaSarah H.HailebDavid C.KaspercThomas P.MechtlercAndreas J.FlammeraPierre A.KrayenbuehldDaniel P.Franzena   University Hospital Zurich, Zurich, Switzerland b University Zurich, Zurich,… Read more